Are accelerators actually making companies better, or just making them easier to sell?

In Episode 8, Neo digs into the uncomfortable gap between the accelerator myth and the post-demo-day reality. Drawing on first-hand experience designing and running programmes in sub-Saharan Africa, she traces how quickly “support” can turn into performance, and why polish is often mistaken for progress.

Then the data lands the punchline. Between January 2024 and mid-2025, Neo analysed 879 funding rounds where an accelerator or incubator appeared as an investor, tracking who raised, who progressed, and who quietly disappeared once the spotlight moved on. The pattern is clear: accelerators show up in meaningful deal volume, but not in proportional capital intensity. In other words, they can improve early legibility without guaranteeing late-stage durability.

This episode unpacks why the top 1–2% of programmes genuinely compound advantage, why most cannot, and how geography quietly tightens the funnel instead of widening it. You’ll hear why accelerators often compress the beginning but do not reliably solve the “middle” where unit economics, distribution, and operational resilience decide whether a business survives.

If you are a founder choosing between credibility and capability, an investor treating “accelerator-backed” as a shortcut, or an ecosystem builder designing programmes with real outcomes, this rant is a practical reset: accelerators are not neutral tools, they shape behaviour. The question is whether they are shaping it towards building real companies, or towards fundraising theatre.

Biotech does not run on software timelines. You cannot sprint biology, you cannot “growth hack” regulation, and you definitely cannot ship a patch when the product is inside a human being.

In this episode, Neo breaks down the uncomfortable mismatch between traditional venture capital’s speed instincts and biotech’s hard constraints, using fresh analysis of nearly 6,000 biotech and health-tech companies (almost 7,000 rounds, roughly $267B in announced investment) across 50+ countries from 2020 to 2025. Through a real investment decision inside a Chinese bone-regeneration startup, she shows why the biggest cheque is often the wrong choice, and why capability, manufacturing readiness, clinical access, and regulatory competence matter more than valuation optics.

China becomes the case study for what happens when biotech is treated as industrial capability rather than a speculative side quest, and why corporate venture capital can be a load-bearing beam when the “long, uncomfortable middle” arrives. If you care about what gets to real patients, this episode is your reality check: in biotech, money is fuel, but infrastructure is the engine.

The AI boom looks historic on the surface. Underneath, the structure tells a very different story.

In this episode, Neo examines what happens when capital flows in exactly the wrong direction. Drawing on analysis of more than 4,000 AI and machine learning startups and over $400 billion in disclosed funding between 2020 and 2025, she shows how a handful of mega-rounds came to dominate what we now call “innovation”.

Nineteen companies absorbed the vast majority of AI capital in 2024, while thousands of others competed for what remained. This rant unpacks why that kind of concentration feels exciting in real time, why it distorts behaviour across the ecosystem, and why the damage often only becomes visible years later.

Using a real marketplace case from the UAE, Neo traces how AI narratives collide with growth-stage reality in markets where Series B capital is scarce, infrastructure costs are high, and ownership of technology matters more than demos. From there, she zooms out to reveal a global pattern: capital clustering around foundation models and infrastructure, application-layer companies being starved of scale capital, and entire regions pushed into performative AI just to stay visible.

This is not an argument against AI. It is an argument about allocation, incentives, and endurance. If you are building, backing, or expanding AI companies and wondering why the boom feels loud but fragile, this episode explains why.

Product-market fit is treated like a verdict in startup culture. Neo argues it is nothing of the sort. In this episode, she reframes “fit” as a sequence of proofs that change by market, infrastructure, climate, and customer behaviour, then stress-tests the idea using food delivery as the clearest real-world case study.

Using fresh analysis of 590 food delivery companies that raised $28B globally between 2020 and 2025, Neo tracks where the story holds and where it collapses, especially at the Series A to Series B filter where optimism stops carrying the business. From Johannesburg’s trust-led reliability, to Kinshasa’s “good enough” certainty, Dubai’s integration-as-infrastructure, and China’s density-driven automation, this rant shows why copying someone else’s playbook is often just an expensive way to misunderstand your own market.

If you have ever asked “do we have product-market fit?”, this episode gives you the better question: what proof are we actually earning next, and will it still hold when subsidies, hype, and convenience disappear.

In this episode, Neo takes innovation on a global tour to examine how geography quietly shapes outcomes in ways our dominant frameworks fail to capture. From Africa’s discipline under scarcity to Southeast Asia’s capital efficiency, the Middle East’s deliberate experiment in enforced accountability, Europe’s structural leakage, Latin America’s resilience, and North America’s blind spots under abundance, this episode asks a sharper question than where innovation happens.

It shows how incentives, capital conditions, and local constraints determine what actually works, and why using universal metrics across non-universal realities leads us to fund familiarity instead of performance. If you have ever wondered why some overlooked ecosystems keep producing durable companies while celebrated ones struggle under scrutiny, this rant explains why.

What if the words we use to describe startup success are quietly misleading us?

In the first episode of A Reasonable Rant, Neo pulls apart the language that dominates the startup and venture world. Terms like scalable, innovative, AI-powered, platform, and product-market fit sound impressive, but often mean very different things depending on who is listening.

Drawing on nearly a decade working across Africa, Asia, the Middle East, and global venture markets, Neo explores how imprecise language hides risk, inflates confidence, and distorts decision-making. Not through hot takes or hype, but through lived experience, acquisition-room lessons, and hard data.

This is not a podcast about tearing startups down. It is about getting closer to what things actually are, so founders, investors, and ecosystem builders can make better decisions.

Part one of a three-part prologue series.
Part two looks at the data that breaks the narrative.
Part three asks what we should be measuring instead.

If you have ever felt that startup language sounds convincing but explains very little, this rant is for you.

In the final episode of the prologue, Neo gets practical. This episode examines why most startup metrics fail outside the environments they were designed for, and what happens when measurement finally matches reality. Drawing on years of fieldwork, expert collaboration, and hundreds of thousands of data points, Neo lays out the signals that actually predict durability, progress, and value when capital is scarce and context matters. If you are still measuring with someone else’s ruler, this episode shows you why nothing fits.

In Part 2, Neo puts startup mythology face to face with real numbers. Drawing on over 10,000 funding events across 74 countries, this episode shows how global benchmarks distort reality, why capital behaves radically differently by geography, and how founders outside dominant markets are often misjudged by metrics never designed for their context. If the data feels uncomfortable, that is the point.